Cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies: a case report
- 19 Downloads
Anti-glutamic acid decarboxylase (GAD) autoantibodies have been first described in patients with diabetes mellitus type 1 (DM1) and then found to be associated with several neurological syndromes including cerebellar ataxia . These antibodies are usually directed against the 65 kDa isoform of the enzyme glutamic acid decarboxylase (GAD65), which produces gamma-aminobutyric acid (GABA) from glutamate in the nerve terminals. In the cerebellum, anti-GAD antibodies impair the GABA-synthesis in the cerebellar basket and stellate cells leading to a reduced inhibitory GABAergic postsynaptic transmission from Purkinje cells .
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
The authors declare that the study has been performed in accordance with ethical standards laid down in the 1964 Declaration of Helsinki.
- 1.Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F (2008) Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 131(Pt 10):2553–2563. https://doi.org/10.1093/brain/awn183. CrossRefPubMedGoogle Scholar
- 2.Manto M, Mitoma H, Hampe CS (2018) Anti-GAD antibodies and the cerebellum: where do we stand? Cerebellum. https://doi.org/10.1007/s12311-018-0986-6.